| RMS / frexalimab vs teriflunomide | EFC17919B | III | 2024 - ongoing |
| Chronic Neuropathic Pain / LY3848575 | J4F-MC-CYAB | II | 2024 - ongoing |
| Migraine prevention / Lu AG09222 | 2023-508821-28 | III | 2024 - ongoing |
| Dementia (Agitation) / AVP-786 | 2023-504990-19 | III | 2023 - ongoing |
| Adults with ADHD / DEXINA | 2022-502903-31 | III | 2023 - ongoing |
| Elecsys® Amyloid Plasma Panel | RD006263 | NIS | 2023 - 2025 |
| Major Depressive Disorder / BH-200 | 2022-002757-26 | II | 2022 - ongoing |
| RMS / BIIB091 Monotherapy | 2022-502552-31 | II | 2022 - ongoing |
| Psychosis (Alzheimer's) / KarXT | 2022-001515-10 | III | 2022 - ongoing |
| Migraine / Atogepant vs Topiramate | 2022-501172-25 | III | 2022 - ongoing |
| Schizophrenia / BI 425809 (CONNEX-3) | 2020-003726-23 | III | 2021 - 2025 |
| RMS / Fenebrutinib vs teriflunomide | 2019-004857-10 | III | 2021 - ongoing |
| Chronic non-specific Back Pain / Ver-01 | 2020-000107-36 | III | 2021 - 2024 |
| Early Alzheimers Disease / semaglutide | 2020-004848-29 | III | 2021 - ongoing |
| Depressive Episode / Silexan | 2020-000688-22 | III | 2021 - 2023 |
| PPMS / Fenebrutinib vs ocrelizumab | 2019-003919-53 | III | 2021 - ongoing |
| Alzheimer's / Aducanumab Open-Label | 2019-004368-22 | IIIb | 2020 - 2024 |
| Small-fibre Neuropathie / BIIB074 | 802NP206 | II | 2019 - 2021 |
| Mild Alzheimer´s disease / BIIB092 | 225AD201 | II | 2018 - 2021 |
| Alzheimers participants at risk | CAPI015A2201J | II/III | 2018 - 2019 |
| Mild Alzheimer-Demenz / DAYBREAK | 015-005625-39 | III | 2017 - 2018 |
| Early stage RRMS / Ocrelizumab | 2016-002937-31 | IIIb | 2017 - ongoing |
| Vision GER-BGT 13-10586 | - | IV | 2016 - 2016 |
| ENGAGE; Aducanumab in Mild AD | 2015-000967-15 | III | 2016 - 2019 |
| RRMS / CASTING; Ocrelizumab | 2015-005597-38 | III | 2016 - ongoing |
| 109MS308 – INSPIRE | - | III | 2015 - ongoing |
| 101MS408 – REVEAL | - | III | 2015 - 2015 |
| Siponimod in SPMS | - | III | 2014 - ongoing |
| 101MS409 – ESCALATE | - | III | 2014 - 2015 |
| CFTY720D2399 – LONGTERMS | - | IV | 2014 - 2015 |
| CFTY720DDE02 - NIS PANGAEA | - | IV | 2013 - ongoing |
| CFTY720DDE17 – START | - | IV | 2013 - 2015 |
| Multiple Regimens Natalizumab (RRMS) | - | II | 2011 - 2013 |
| Natalizumab in SPMS | - | III | 2011 - 2013 |
| RRMS (Natalizumab to Fingolimod) | - | IIIb | 2011 - 2012 |
| Fingolimod & AntiD in RRMS | - | II | 2010 - 2012 |
| Siponimod (Optic Neuritis) | - | II | 2010 - 2012 |
| Sativex safety registry | - | Obs. | 2010 - 2014 |
| Belilumab in Myasthenia Gravis | - | II | 2010 - 2015 |
| RRMS / Ono4641 | - | II | 2010 - 2012 |
| RRMS / Daclizumab | - | II | 2010 - 2013 |
| RRMS / FTY (Examining Physician) | - | III | 2010 - 2012 |
| RRMS / FTY (Principle Investigator) | - | III | 2010 - 2012 |
| RRMS / FTY (Treating Physician) | - | III | 2010 - 2012 |
| RRMS / Ocrelizumab | - | II | 2008 - 2012 |
| RRMS / FTY (Examining Physician) | - | III | 2008 - 2011 |
| Thymectomy in Myasthenia Gravis | - | Eval. | 2007 - 2012 |